Abstract
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Biomarkers, Pharmacological / blood*
-
Biomarkers, Tumor / blood
-
Cell Cycle Checkpoints / drug effects
-
Cell Cycle Checkpoints / immunology
-
Cohort Studies
-
Female
-
Humans
-
Interleukin-8 / blood*
-
Male
-
Neoplasms / blood
-
Neoplasms / diagnosis
-
Neoplasms / drug therapy*
-
Neoplasms / mortality
-
Neutrophil Infiltration / drug effects
-
Neutrophils / pathology*
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use*
-
Retrospective Studies
-
Survival Analysis
-
Treatment Failure
-
Tumor Microenvironment / immunology
-
Up-Regulation
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents, Immunological
-
Biomarkers, Pharmacological
-
Biomarkers, Tumor
-
Interleukin-8
-
Protein Kinase Inhibitors